MX2022003063A - Composiciones terapeuticas, combinaciones y metodos de uso. - Google Patents

Composiciones terapeuticas, combinaciones y metodos de uso.

Info

Publication number
MX2022003063A
MX2022003063A MX2022003063A MX2022003063A MX2022003063A MX 2022003063 A MX2022003063 A MX 2022003063A MX 2022003063 A MX2022003063 A MX 2022003063A MX 2022003063 A MX2022003063 A MX 2022003063A MX 2022003063 A MX2022003063 A MX 2022003063A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
combination
inhibitor
chs
Prior art date
Application number
MX2022003063A
Other languages
English (en)
Inventor
Udai Banerji
Original Assignee
The Institute Of Cancer Res Royal Cancer Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Institute Of Cancer Res Royal Cancer Hospital filed Critical The Institute Of Cancer Res Royal Cancer Hospital
Publication of MX2022003063A publication Critical patent/MX2022003063A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a métodos que comprenden la administración de un inhibidor de FAK (por ejemplo, VS-6063) en combinación con un inhibidor dual de RAF/MEK (por ejemplo, CH5126766) que son útiles en el tratamiento del crecimiento celular anormal, como el cáncer, en un sujeto como tal como humanos.
MX2022003063A 2019-09-13 2020-09-11 Composiciones terapeuticas, combinaciones y metodos de uso. MX2022003063A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2019/074565 WO2021047783A1 (en) 2019-09-13 2019-09-13 Vs-6063 in combination with ch5126766 for the treatment of cancer
PCT/EP2020/075455 WO2021048339A1 (en) 2019-09-13 2020-09-11 Vs-6063 in combination with ch5126766 for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2022003063A true MX2022003063A (es) 2022-06-14

Family

ID=67988988

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003063A MX2022003063A (es) 2019-09-13 2020-09-11 Composiciones terapeuticas, combinaciones y metodos de uso.

Country Status (11)

Country Link
US (2) US11517573B2 (es)
EP (1) EP4028010A1 (es)
JP (2) JP2022547358A (es)
KR (1) KR20220078606A (es)
CN (1) CN114630667A (es)
AU (1) AU2020344829A1 (es)
BR (1) BR112022004699A2 (es)
CA (1) CA3152805A1 (es)
MX (1) MX2022003063A (es)
TW (1) TW202114677A (es)
WO (3) WO2021047783A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023503897A (ja) * 2019-11-18 2023-02-01 ▲應▼世生物科技（南京）有限公司 Ｎｒａｓ変異を有する腫瘍を治療するための医薬品の調製におけるｆａｋ阻害剤の使用
WO2022015736A1 (en) * 2020-07-13 2022-01-20 Verastem, Inc. Combination therapy for treating abnormal cell growth
AU2022318885A1 (en) * 2021-07-27 2024-02-08 Francis Crick Institute Combination therapy for treating abnormal cell growth
AU2022376939A1 (en) * 2021-10-28 2024-05-02 Verastem, Inc. Combination therapy for treating abnormal cell growth
CA3236424A1 (en) * 2021-11-02 2023-05-11 Verastem, Inc. Methods of treating abnormal cell growth
WO2023138630A1 (zh) * 2022-01-21 2023-07-27 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
CN114917232A (zh) * 2022-06-27 2022-08-19 厦门骨本生物科技有限公司 Ch5126766在制备缓解或治疗动物骨关节炎的药物中的应用
CN115177622A (zh) * 2022-07-19 2022-10-14 中南大学湘雅二医院 多个化合物在制备治疗骨髓增殖性肿瘤的药物中的应用
CN117582504A (zh) * 2022-08-15 2024-02-23 海创药业股份有限公司 一种治疗卵巢癌的联合用药物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9920908D0 (en) 1999-09-03 1999-11-10 Indena Spa Chalcone coumarins
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
KR101132880B1 (ko) 2007-04-18 2012-06-28 화이자 프로덕츠 인크. 비정상적인 세포 성장의 치료를 위한 술포닐 아미드 유도체
US8569378B2 (en) 2007-07-20 2013-10-29 Toshiyuki Sakai p27 protein inducer
US20110086837A1 (en) 2009-10-12 2011-04-14 Genentech, Inc. Combinations of a pi3k inhibitor and a mek inhibitor
WO2012045194A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
AR084216A1 (es) 2010-12-09 2013-05-02 Sanofi Sa Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
US20130004481A1 (en) 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
US9133174B2 (en) 2011-09-05 2015-09-15 Chugai Seiyaku Kabushiki Kaisha Method for producing coumarin derivative
WO2013170066A1 (en) 2012-05-09 2013-11-14 H. Lee Moffitt Cancer Center & Research Institute, Inc. Peptides for the treatment of cancer
EP3545968A1 (en) 2012-06-08 2019-10-02 F. Hoffmann-La Roche AG Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
EP2906215A4 (en) 2012-10-12 2016-05-18 SUITS
EP3091981B1 (en) 2014-01-09 2021-03-10 Verastem, Inc. Compositions and methods for treatment of abnormal cell growth
EP3102232B1 (en) 2014-02-07 2020-02-05 Verastem, Inc. Methods and compositions for treating abnormal cell growth
WO2017004192A1 (en) 2015-06-29 2017-01-05 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
CA3074690A1 (en) * 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
WO2019096397A1 (en) 2017-11-16 2019-05-23 The Institute Of Cancer Research: Royal Cancer Hospital Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder

Also Published As

Publication number Publication date
BR112022004699A2 (pt) 2022-06-14
US20230277535A1 (en) 2023-09-07
TW202114677A (zh) 2021-04-16
US11517573B2 (en) 2022-12-06
KR20220078606A (ko) 2022-06-10
JP2022547358A (ja) 2022-11-14
US20220031698A1 (en) 2022-02-03
CA3152805A1 (en) 2021-03-18
WO2021048339A1 (en) 2021-03-18
EP4028010A1 (en) 2022-07-20
WO2021047798A1 (en) 2021-03-18
JP2022172480A (ja) 2022-11-17
CN114630667A (zh) 2022-06-14
WO2021047783A1 (en) 2021-03-18
AU2020344829A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
MX2022003063A (es) Composiciones terapeuticas, combinaciones y metodos de uso.
CR20210415A (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidoria en cdk2
ZA201800572B (en) Therapeutic compositions, combinations, and methods of use
PH12020551923A1 (en) Methods and compositions for treating cancer
ZA201905488B (en) Tigit- and light-based chimeric proteins
GB2557123A (en) Modified cells and methods of therapy
MX2022005216A (es) Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7).
WO2016109546A3 (en) Methods and compositions for prognosis and treatment of cancers
MX2020010369A (es) Particulas implantables y metodos relacionados.
MX2022009347A (es) Terapia de combinacion para el tratamiento del crecimiento celular anormal.
MX2021014286A (es) Proteinas multiespecificas.
PH12020552135A1 (en) Kdm1a inhibitors for the treatment of disease
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
MX2021005395A (es) Terapia del cáncer con células inmunitarias anti-liv1.
MX2022001004A (es) Inhibidores de enzimas.
AU2018337668A1 (en) Improved supraparticles
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy
MX2021012894A (es) Compuestos ciclicos de fosfato.
WO2019169333A8 (en) Afibrotic compounds, devices, and uses thereof
TN2018000351A1 (en) Oxaborole esters and uses thereof
MX2021000555A (es) Tratamiento antidiabetico cardiovascular seguro.
MX2021014905A (es) Células seguras e invisibles para el sistema inmunitario.
WO2022218941A3 (en) Compositions and methods for inhibiting ketohexokinase (khk)
MX2020013446A (es) Terapia de combinacion.
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.